Suppr超能文献

C31G羟乙基纤维素凝胶在女性中连续一周每日单次使用的安全性。

Safety of single daily use for one week of C31G HEC gel in women.

作者信息

Ballagh S A, Baker J M, Henry D M, Archer D F

机构信息

Eastern Virginia Medical School, 601 Colley Avenue, Norfolk, VA 23507-1627, USA.

出版信息

Contraception. 2002 Nov;66(5):369-75. doi: 10.1016/s0010-7824(02)00433-x.

Abstract

Genital irritation and user acceptability was compared after seven nightly bedtime exposures to 1.2% C31G hydroxyethyl cellulose (HEC), 2% nonoxynol-9 (N-9) (Gynol II) or HEC vehicle alone. Sixty healthy women over 18 years old at low risk for sexually transmitted disease with normal menses were randomly assigned to one of three groups. Entrance and exit pelvic exams documented vaginal pH and Gram stain. Genital irritation was assessed by patient diaries, a telephone call 24 to 48 h after first use, colposcopy done the day after last product use, and an acceptability questionnaire at exit. Eighty percent of the women using C31G HEC experienced symptoms of vaginal burning or heat compared to 25% of the N-9 users and 5% of the vehicle users. Colposcopic findings were similar for the active treatments of C31G HEC and N-9: 50% vs. 60% developed new lesions, 25% vs. 20% had lesions that disrupted epithelial integrity, and 50% vs. 45% had minor lesions, respectively. Findings with the HEC vehicle were half as frequent. Twelve percent of women had epithelial disruption that was assessed by the colposcopist as applicator-related. Gram stains were half as likely to show bacterial vaginosis after N-9 use (6 --> 3) and one fourth as likely after vehicle or C31G HEC use (4 --> 1). When asked if they would use the product if it were an effective contraceptive, 55% of the vehicle users, 35% of the N-9 users, and 25% of the C31G HEC users agreed. Product acceptability of C31G HEC was limited by the sensation of heat or burning. The C31G HEC product had a similar safety profile to N-9 in this comparative trial.

摘要

在连续七个夜间就寝时接触1.2% C31G羟乙基纤维素(HEC)、2%壬苯醇醚-9(N-9)(Gynol II)或仅使用HEC赋形剂后,对生殖器刺激和使用者可接受性进行了比较。60名18岁以上、性传播疾病低风险且月经正常的健康女性被随机分配到三组中的一组。入组和出组时的盆腔检查记录了阴道pH值和革兰氏染色。通过患者日记、首次使用后24至48小时的电话随访、最后一次使用产品次日的阴道镜检查以及出组时的可接受性问卷来评估生殖器刺激。使用C31G HEC的女性中有80%出现阴道烧灼感或发热症状,而使用N-9的女性为25%,使用赋形剂的女性为5%。C31G HEC和N-9的活性治疗的阴道镜检查结果相似:分别有50%对60%出现新病变,25%对20%的病变破坏上皮完整性,以及50%对45%有轻微病变。HEC赋形剂组的发现频率为前两者的一半。12%的女性存在上皮破坏,经阴道镜检查人员评估与 applicator 相关。使用N-9后革兰氏染色显示细菌性阴道病的可能性减半(从6降至3),使用赋形剂或C31G HEC后可能性降至四分之一(从4降至1)。当被问及如果该产品是一种有效的避孕药,她们是否会使用时,55%的赋形剂使用者、35%的N-9使用者和25%的C31G HEC使用者表示同意。C31G HEC的产品可接受性受到热感或烧灼感的限制。在这项比较试验中,C31G HEC产品的安全性与N-9相似。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验